Table 1

Patient demographics

Patient characteristicsTreg-TconHistorical controlsP value
Number of patients 43 114  
M/F 20/23 63/51 .5 
Age, y (median and range) 40 (range 18-65) 37 (range 8-66) .8 
Median time and range from diagnosis to transplant, CR1 6 mo (3-48) 5 mo (2-55) .4 
Median length of remission and range, CR2 6.5 mo (1-60) 7 mo (2-55) .6 
Disease and status    
 ALL 10 (23%) 50 (44%) .08 
  1 CR 27  
  ≥II CR 23  
 AML 33 (77%) 64 (56%) .07 
  1 CR 18 30  
  ≥II CR 15 34  
NK cell alloreactivity    
 ALL 10 50  
  Yes 3 (30%) 19 (38%) .6 
  No 7 (70%) 31 (62%) .7 
 AML 33 64  
  Yes 14 (43%) 32 (50%) .5 
  No 19 (57%) 32 (50%) .4 
High-risk CR1 25 (58%) 67 (59%) .8 
 Induction failure  
 Secondary 10  
 T(9;22) 11  
 Bilineage leukemia  
 Complex karyotype 10  
 FLT3 ITD NA  
 WBC >50 000/mmc at diagnosis for ALL 10  
Patient characteristicsTreg-TconHistorical controlsP value
Number of patients 43 114  
M/F 20/23 63/51 .5 
Age, y (median and range) 40 (range 18-65) 37 (range 8-66) .8 
Median time and range from diagnosis to transplant, CR1 6 mo (3-48) 5 mo (2-55) .4 
Median length of remission and range, CR2 6.5 mo (1-60) 7 mo (2-55) .6 
Disease and status    
 ALL 10 (23%) 50 (44%) .08 
  1 CR 27  
  ≥II CR 23  
 AML 33 (77%) 64 (56%) .07 
  1 CR 18 30  
  ≥II CR 15 34  
NK cell alloreactivity    
 ALL 10 50  
  Yes 3 (30%) 19 (38%) .6 
  No 7 (70%) 31 (62%) .7 
 AML 33 64  
  Yes 14 (43%) 32 (50%) .5 
  No 19 (57%) 32 (50%) .4 
High-risk CR1 25 (58%) 67 (59%) .8 
 Induction failure  
 Secondary 10  
 T(9;22) 11  
 Bilineage leukemia  
 Complex karyotype 10  
 FLT3 ITD NA  
 WBC >50 000/mmc at diagnosis for ALL 10  

F, female; M, male; NA, not applicable; WBC, white blood cell.

or Create an Account

Close Modal
Close Modal